CEL-SCI Corp (CVM) –
-
Form 3 CEL SCI CORP For: Apr 19 Filed by: Gobbo Mario
-
Form 4 CEL SCI CORP For: Apr 19 Filed by: Watson Robert Eugene
-
Form 4 CEL SCI CORP For: Apr 19 Filed by: BAILLAVOINE BRUNO JEAN-MARIE
-
Form 4 CEL SCI CORP For: Apr 19 Filed by: TALOR EYAL
-
Form 4 CEL SCI CORP For: Apr 19 Filed by: PRICHEP PATRICIA B
-
Form 4 CEL SCI CORP For: Apr 19 Filed by: KERSTEN GEERT R
-
Form 8-K CEL SCI CORP For: Apr 19
-
CEL-SCI Corp (CVM) Appoints Mario Gobbo to Its Board
-
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
-
Form 8-K CEL SCI CORP For: Apr 19
-
Form 4 CEL SCI CORP For: Mar 29 Filed by: TALOR EYAL
-
Form 4 CEL SCI CORP For: Mar 29 Filed by: PRICHEP PATRICIA B
-
Form 4 CEL SCI CORP For: Mar 29 Filed by: KERSTEN GEERT R
-
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
-
Form ARS CEL SCI CORP For: Dec 31
-
Form DEFA14A CEL SCI CORP
-
Form DEF 14A CEL SCI CORP For: Mar 01
-
CEL-SCI Corp (CVM) Issues Letter to Shareholders
-
CEL-SCI Corporation Issues Letter to Shareholders
-
CEL-SCI Corp (CVM) Reports In-Line Q1 EPS
-
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
-
Form 10-Q CEL SCI CORP For: Dec 31
-
Form 8-K CEL SCI CORP For: Feb 08
-
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
-
Form 424B5 CEL SCI CORP
-
CEL-SCI Corp (CVM) Prices 3.875M Share Offering at $2/sh
-
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
-
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
-
Form 4 CEL SCI CORP For: Dec 29 Filed by: TALOR EYAL
-
Form 4 CEL SCI CORP For: Dec 29 Filed by: PRICHEP PATRICIA B
-
Form 4 CEL SCI CORP For: Dec 29 Filed by: KERSTEN GEERT R
-
Form S-8 CEL SCI CORP
-
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
-
Form 10-K CEL SCI CORP For: Sep 30
-
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
-
Form 8-K CEL SCI CORP For: Nov 15
-
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
-
Form 424B5 CEL SCI CORP
-
CEL-SCI Corp (CVM) Prices 2.49M Share Offering at $2/sh
-
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
-
Form 8-K CEL SCI CORP For: Oct 26
-
CEL-SCI (CVM) Issues Letter to Shareholders
-
CEL-SCI Issues Letter to Shareholders
-
Form 8-K CEL SCI CORP For: Oct 23
-
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
-
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
-
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
-
CEL-SCI Corp (CVM) Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
-
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
-
Form 4 CEL SCI CORP For: Sep 29 Filed by: TALOR EYAL
Back to CVM Stock Lookup
